{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:44Z","timestamp":1740134864885,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,12]]},"DOI":"10.1182\/blood.2021011774","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T15:33:34Z","timestamp":1628782414000},"page":"421-422","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Expanding landscape for relapsed Hodgkin lymphoma"],"prefix":"10.1182","volume":"138","author":[{"given":"Yun","family":"Choi","sequence":"first","affiliation":[{"name":"Perlmutter Cancer Center at NYU Langone Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1116-3246","authenticated-orcid":false,"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center at NYU Langone Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"issue":"6","key":"2021081215332933300_B1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2021081215332933300_B2","first-page":"749","article-title":"Hodgkin\u2019s disease: the role of bone marrow transplantation","volume":"17","author":"Vose","year":"1990","journal-title":"Semin Oncol"},{"key":"2021081215332933300_B3","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127575","article-title":"High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma [abstract]","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"2021081215332933300_B4","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123162","article-title":"PET-adapted nivolumab or nivolumab plus ice as first salvage therapy in relapsed or refractory Hodgkin lymphoma [abstract]","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood"},{"key":"2021081215332933300_B5","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123879","article-title":"Safety and toxicity profile of pembrolizumab (PEM) in combination with ICE chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory classical Hodgkin lymphoma: no impairment in stem cell mobilization or engraftment [abstract]","volume":"134","author":"Bryan","year":"2019","journal-title":"Blood"},{"issue":"21","key":"2021081215332933300_B6","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2021081215332933300_B7","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"2021081215332933300_B8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2021081215332933300_B9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","article-title":"Checkpoint blockade treatment may sensitize hodgkin lymphoma to subsequent therapy","volume":"25","author":"Carreau","year":"2020","journal-title":"Oncologist"},{"key":"2021081215332933300_B10","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123925","article-title":"Brentuximab vedotin in first refractory\/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. final analysis of phase II study [abstract]","volume":"134","author":"Stamatoullas","year":"2019","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/6\/421\/1817095\/bloodbld2021011774c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/6\/421\/1817095\/bloodbld2021011774c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T15:33:45Z","timestamp":1628782425000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/6\/421\/476505\/Expanding-landscape-for-relapsed-Hodgkin-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,13]]},"published-print":{"date-parts":[[2021,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021011774","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2021,4,13]]}}}